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ARTIGO DE REVISÃO 
PATOFISIOLOGIA DA DOR ONCOLÓGICA: REVISÃO DE 
LITERATURA 
PATHOPHYSIOLOGY OF ONCOLOGICAL PAIN: REVIEW OF 
LITERATURE 
Lucas Yago Souza Schmidt¹, Ana Flávia de Oliveira Castro¹, João Gabriel Lopes 
Siqueira², Dowglas Pereira de Oliveira¹, Welma Rezende Fuso de Assis³. 
RESUMO 
Apesar dos insumos à diagnose e terapêutica do câncer, a doença continua 
trazendo agravo à qualidade de vida dos enfermos, sendo a dor referida como 
queixa frequente, com prevalência variando entre 50 e 53% em pacientes com 
câncer em todos os estágios, e até 70% nos casos de doença avançada. A dor 
oncológica se manifesta conforme a localização primária do câncer, metástase, 
acometimento ósseo, proximidade com sistema nervoso, produção de substâncias 
químicas promotoras da dor, e fatores relacionados ao paciente como ansiedade e 
depressão. Por ser subjetiva, não palpável, e uma experiência individual e de difícil 
avaliação, requer para a equipe de saúde suporte educacional, conhecimento e 
instrumentos que contribuam para a sua compreensão, sendo a elucidação de 
seus mecanismos biológicos objeto desta revisão de literatura. 
Palavras-chave: Dor Oncológica. Dor. Cuidados Paliativos. Fisiologia da dor. 
 
ABSTRACT 
Despite the contributions to the diagnosis and treatment of cancer, the disease 
continues to present an adverse effect on patients' quality of life, with pain being 
a frequent complaint, with a prevalence varying from 50 to 53% in cancer patients 
at all stages and up to 70 % in cases of advanced disease. Cancer pain is 
manifested by the primary site of cancer, metastasis, bone involvement, proximity 
to the nervous system, production of pain-promoting chemicals, and patient-
related factors such as anxiety and depression. Because it is subjective, not 
palpable, and an individual experience and difficult to evaluate, requires for the 
health team educational support, knowledge and instruments that contribute to 
their understanding, being the elucidation of its biological mechanisms object of 
this literature review. 
Keywords: Oncologic Pain. Pain. Paliative Care. Physiology of pain. 
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INTRODUCTION 
 
Despite the inputs to the diagnosis and treatment of 
cancer, the disease continues to affect the quality of life of the 
population, and pain is reported as a frequent complaint, 
affecting approximately 50% of the patients in all stages of the 
disease and around 70% of the patients cases of advanced 
disease1,7.  
The oncologic pain is manifested due to the growth of 
the primary tumor or its metastases, to the research methods 
and even as an effect of the usual treatment therapies, such 
as chemotherapy and radiotherapy2. Its management should 
be prioritized through the impact on physical activity, 
appetite, sleep, mood and quality of life of the individual in 
the process of coping with the disease, reflecting on psychic 
suffering, questions of a metaphysical nature and aggravation 
of endocrine-immunological parameters3,7. 
According to the World Health Organization (WHO) 
estimate, of the 5 million people who die of cancer each year, 
4 million die from uncontrolled pain, and most cases are 
effectively attenuated by pharmacological interventions and 
mental relaxation techniques.4 
Cancer pain relief involves a global intervention that 
considers the physical, social, psychological, emotional, and 
spiritual aspects of suffering, called palliative treatment. The 
palliative treatment integrates a therapeutic plan for the 
patient who does not respond to the curative treatment, 
aiming to promote quality of life and well-being to this and 
their relatives in the psychosocial-emotional-biological 
environments - it also implements the curative treatment of 
cancer in its earliest stages. 5,12 
The pain symptom is an unpleasant sensory and 
emotional experience with intensity proportional to the 
disease progression, varying according to the primary location 
of the cancer, metastasis, bone involvement, proximity to the 
nervous system, production of pain-promoting chemicals, and 
factors related to the patient as anxiety and depression. In 
addition, pain intensity is the preponderant factor to predict 
the need for pain relief.12 
According to the International Society for the Study of 
Pain, pain is "an unpleasant sensory and emotional 
experience, which is described in terms of actual or potential 
tissue damage. Pain is always subjective and each individual 
learns to use.”5 Because it involves diverse and complex 
aspects, the management of cancer pain requires the 
evaluation and treatment of the physical, emotional, social 
and spiritual components5,12, being the biological dimension 
the purpose of this article. 
 
METHODOLOGY 
  
The information contained in this study was obtained 
by bibliographic survey of specialized literature present in 
books, guidelines, consensuses and periodicals in the English 
and Portuguese language published on the free access 
platforms PubMed and LILACS (Latin American and Caribbean 
Literature in Health Sciences), using the descriptors Oncologic 
Pain, Pain, Palliative Care and Physiology of Pain. It 
wasobtained a sample of 13 publications, useful to the 
discussion of the developed theme. 
RESULTS AND DISCUSSION 
Epidemiology 
 It is estimated that in 2012 there were 14.1 million 
new cases of cancer and 8.2 million deaths due to this cause in 
the world, according to the conclusion of the V revision of 
GLOBOCAN. Lung cancer ranks first in incidence, and 
mortality, followed respectively by breast, colorectal, 
prostate, stomach and liver, accounting for 55% of the overall 
incidence this year. As of 2025, more than 20 million new 
cases of cancer are expected annually, especially in developing 
and undeveloped countries7,13. 
 
Pathophysiology 
The primary neurons of the pain pathway, called 
sensory afferent neurons, innervate the skin and almost all of 
the internal organs. They are the gateway to the transmission 
of sensory information from peripheral tissues to the medulla 
and brain, capable of detecting varieties of stimulus types, 
encompassing those of a physical and/or chemical nature 
through their different receptors and transduction 
molecules5,8. 
The cell bodies of the sensory fibers that innervate 
the head and body are located in the trigeminal ganglion and 
dorsal root ganglia, respectively, and fall into two main 
categories: larger diameter myelinated A fibers and 
unmyelinated C fibers , of smaller diameter. Most myelinated 
A-beta fibers carry non-harmful stimuli applied to the skin, 
joints and muscles. In addition, a large part of the myelinated 
non-myelinated C-sensory and A-delta sensory fibers are 
specialized and called nociceptors. These have the function of 
identifying and converting environmental stimuli - thermal, 
mechanical, chemical - harmful, into electrochemical signals 
transmitted to the central nervous system5,8. 
In order to detect noxious stimuli, nociceptors 
express a complex set of receptors that are activated by 
proinflammatory factors released by damaged tissue, are 
these protons, endothelin, prostaglandin, bradykinin and 
neural growth factor. Vanyloid (VR1) receptors, expressed by 
most nociceptors, detect heat, acid, extracellular protons and 
lipid metabolites. To detect harmful mechanical stimuli, they 
activate signaling cascade in response to excessive stretching 
and ATP-activated receptors8. 
The plasticity of sensory neurons allows the change of 
their phenotype in response to a sustained peripheral lesion 
that alters peptide-signaling patterns and expression of tissue 
growth factors.This change depends, in part, on peripheral 
sensitization, in which the level of activation of the nociceptor 
threshold is reduced, so that what would normally be 
perceived as a mild noxious stimulus is perceived as highly 
harmful - hyperalgesia - or stimuli that normally would be 
perceived as non-harmful are perceived as harmful - allodynia. 
Peripheral tissue damage has also been shown to previously 
activate "silent" or "dormant" nociceptors, making them 
highly responsive to normally non-harmful or slightly harmful 
stimuli5,6,8. 
Research has shown that peripheral sensitization of 
nociceptors is closely involved in the origin and maintenance 
of pain associated with bone cancer5. 
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A tumor is made up of cancerous cells and other 
types, such as cells of the immune system constituting 
macrophages, neutrophils and T cells, which secrete direct or 
excitatory sensitizing factors from primary afferent neurons, 
including prostaglandins, tumor necrosis factor alpha, 
endothelin, growth factor vascular endothelial (VEGF), 
interleukin 1 and 6, tissue growth factor, platelet derived 
growth factor. Tumors are not predominantly innervated by 
sensory neurons, however growth and proteolytic enzymes 
damage the nerves by compression and by direct proteolysis, 
respectively, resulting in neuropathic pain6,8. 
The transmission of the sensory stimulus to the spinal 
cord neurons of the spinal cord ascends through the 
spinothalamic tract to the CNS and through different parallel 
neuronal pathways, which explains the pain being described 
predominantly of high intensity. The amygdala and the 
cerebral cortex can modulate the ascending conduction of 
pain, justifying the influence of the patient's mood and 
attitude in determining the degree and degree of pain5,8. 
Irruptive pain is characterized by a transient 
accentuation of previously moderate pain intensity, despite 
the administration of analgesic therapy, which may be 
intermittent, related or not to movement, indicative of 
inadequate management of analgesic therapy. 64 to 90% of 
patients with cancer pain experience this type. In most cases 
the etiology is primarily neoplastic (76%) or secondary to 
treatment (20%). Some factors are related to the precipitation 
of the seizures, they are movement, ambulation, coughing, 
orthostatism, intestinal constipation, urinary infection and 
regurgitation of the medication. About 33%, 27%, 20% and 
20% of the irruptive pains are somatic, neuropathic, visceral 
and mixed, respectively9. 
CONCLUSION 
 The management of pain in cancer patients aims at 
the overall rehabilitation of the individual in a biopsychosocial 
perspective, and the biological understanding of pain by the 
health professional is a basic component of care planning4. 
Because it is subjective, not palpable, and an 
individual experience and difficult to evaluate, it requires the 
health team to provide educational support, knowledge and 
instruments that contribute to their comprehension5, which 
ends up reducing or eliminating the use of inadequate 
analgesic regimes, underestimation of pain and the 
dissemination of misconceptions about cancer pain. 
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